Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source